'It was not easy' - EMA policy chief on new trial data disclosure policy
This article was originally published in SRA
Executive Summary
Few people in the drug regulatory sphere can be unaware of the travails that have beset the European Medicines Agency's controversial policy on the proactive disclosure of clinical trial data, which has been two and a half years in the making and will come into effect at the beginning of next year1.